Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 1.90B | 2.02B | 1.81B | 1.63B | 1.61B | 1.65B |
Gross Profit | 1.74B | 1.82B | 1.66B | 1.50B | 1.49B | 1.53B |
EBITDA | 1.40B | 1.48B | 1.33B | 1.17B | 1.15B | 1.17B |
Net Income | 922.15M | 976.46M | 873.81M | 782.58M | 758.41M | 767.46M |
Balance Sheet | ||||||
Total Assets | 6.53B | 6.98B | 6.18B | 5.38B | 4.80B | 4.29B |
Cash, Cash Equivalents and Short-Term Investments | 6.12B | 6.57B | 5.83B | 5.05B | 4.48B | 3.97B |
Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Total Liabilities | 382.20M | 419.83M | 397.11M | 289.12M | 316.63M | 392.51M |
Stockholders Equity | 6.15B | 6.56B | 5.78B | 5.09B | 4.48B | 3.89B |
Cash Flow | ||||||
Free Cash Flow | 2.95M | 943.24M | 960.17M | 730.59M | 687.77M | 839.94M |
Operating Cash Flow | 2.95M | 949.47M | 964.78M | 730.59M | 689.67M | 841.75M |
Investing Cash Flow | 0.00 | -6.24M | -4.47M | 1.26M | -1.90M | -2.25M |
Financing Cash Flow | 0.00 | -204.05M | -181.56M | -168.61M | -175.03M | -213.42M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | ¥430.11B | 28.47 | 1.75% | 7.49% | 1.09% | ||
74 Outperform | ¥776.87B | 33.86 | 14.25% | 1.04% | 6.67% | 114.29% | |
73 Outperform | ¥19.83B | 18.53 | 1.31% | 8.97% | 13.17% | ||
73 Outperform | $12.08T | 30.87 | 22.31% | 0.29% | 4.13% | 20.26% | |
68 Neutral | ¥267.16B | 11.13 | 10.56% | 2.69% | 19.94% | ― | |
66 Neutral | ¥370.28B | 13.49 | 2.24% | 2.50% | 5.33% | -16.64% | |
60 Neutral | ¥3.35B | 76.29 | 1.43% | 13.67% | -63.44% |
Temairazu, Inc. reported an 8% increase in net sales and a 13% rise in profit for the nine months ending March 31, 2025, compared to the previous year. The company’s strong financial performance reflects its effective market strategies and solidifies its position in the industry, with a notable equity-to-asset ratio of 96.3%, indicating robust financial health and stability.